Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Antimicrobial Stewardship

Background:

• Ventilator-associated pneumonia (VAP) is a common ICU infection, historically treated with prolonged antibiotic courses.
• This extensive antimicrobial exposure contributes to resistance and toxicity.
• Current evidence supports shorter treatment durations for VAP.

Purpose of the Study:

• To review current evidence and guidelines on VAP treatment duration.
• To provide a practical framework for clinicians on optimizing antibiotic therapy for VAP.
• To highlight the role of individualized treatment and biomarkers in VAP management.

Main Methods:

• Narrative review synthesizing guideline recommendations and trial evidence.
• Analysis of data from randomized trials and meta-analyses, including the REGARD-VAP trial.
• Discussion of pathogen- and patient-specific factors influencing treatment duration.

Main Results:

• Shorter-course therapy (~7 days) is non-inferior to longer courses for most immunocompetent VAP patients.
• Reduced antibiotic-related toxicity observed with shorter durations, even in complex cases.
• Biomarker-guided discontinuation, like procalcitonin, can reduce antibiotic exposure.

Conclusions:

• A default antibiotic duration of approximately 7 days is recommended for VAP.
• Treatment extension should be individualized based on clinical response, bacteremia, and patient factors.
• Integrating clinical assessment with biomarkers supports effective antimicrobial stewardship in VAP.